Xiaoling Wu
- Cancer Research top 10%
- Cancer-related molecular mechanisms research 7
- Cancer, Hypoxia, and Metabolism 4
- Hepatology top 10%
- Oncology top 10%
- Cancer-related Molecular Pathways 7
- Cancer Cells and Metastasis 6
- Health top 10%
-
- RNA modifications and cancer 8
- Ubiquitin and proteasome pathways 5
-
- Liver Disease Diagnosis and Treatment 6
- Sepsis Diagnosis and Treatment 6
- Cited by
- Cancer ResearchHepatologyOncology
- Partner nations
- ChinaUnited StatesHong Kong
In The Last Decade
Xiaoling Wu
71 papers receiving 1.4k citations
Hit Papers
Peers
Comparison fields: 5 of 137
- Cancer Research 219
- Hepatology 75
- Oncology 256
- Health 64
- Health, Toxicology and Mutagenesis 98
Countries citing papers authored by Xiaoling Wu
This map shows the geographic impact of Xiaoling Wu's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Xiaoling Wu with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Xiaoling Wu more than expected).
Fields of papers citing papers by Xiaoling Wu
This network shows the impact of papers produced by Xiaoling Wu. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Xiaoling Wu. The network helps show where Xiaoling Wu may publish in the future.
Co-authorship network
The 25 scholars most cited alongside Xiaoling Wu, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2025 | 0 | |
| 2 | 2025 | 0 | |
| 3 | 2024 | 0 | |
| 4 | 2024 | 0 | |
| 5 | 2024 | 8 | |
| 6 | 2023 | 1 | |
| 7 | 2023 | 0 | |
| 8 | 2023 | 21 | |
| 9 | 2023 | 5 | |
| 10 | 2020 | 29 | |
| 11 | 2019 | 32 | |
| 12 | 2019 | 0 | |
| 13 | 2017 | 1 | |
| 14 | Macrophage functional phenotype can be consecutively and reversibly shifted to adapt to microenvironmental changes. | 2015 | 30 |
| 15 | 2014 | 43 | |
| 16 | The Role of Src in Gastric Cancer | 2012 | 1 |
| 17 | 2012 | 11 | |
| 18 | 2010 | 17 | |
| 19 | 2007 | 83 | |
| 20 | 2005 | 27 |
About Xiaoling Wu
Xiaoling Wu is a scholar working on Cancer Research, Hepatology, Neuropsychology and Physiological Psychology, Oncology and Epidemiology, having authored 81 papers that have together received 1.5k indexed citations. Recurring topics across this work include RNA modifications and cancer (8 papers), Cancer-related Molecular Pathways (7 papers), Cancer-related molecular mechanisms research (7 papers), Cancer Cells and Metastasis (6 papers), Liver Disease Diagnosis and Treatment (6 papers), Sepsis Diagnosis and Treatment (6 papers), Ubiquitin and proteasome pathways (5 papers) and Cancer, Hypoxia, and Metabolism (4 papers). The work is most often cited by research in Cancer Research (219 citations), Hepatology (75 citations), Oncology (256 citations), Health (64 citations) and Health, Toxicology and Mutagenesis (98 citations). Xiaoling Wu has collaborated with scholars based in China, United States and Hong Kong. Frequent co-authors include Maigeng Zhou, Jiangmei Liu, Jinling You, Yue Cai, Li Y, Lijun Wang, Peng Yin, Andrew Page, Shiwei Liu and Alan D López. Their work appears in journals such as Aging, Oncology Reports, Gene, Virology Journal and Cell Death and Disease.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.